Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 4—April 2011
Dispatch

Hepatitis A Virus Vaccine Escape Variants and Potential New Serotype Emergence

Unai Pérez-Sautu1, M. Isabel Costafreda1, Joan Caylà, Cecilia Tortajada, Josep Lite, Albert Bosch, and Rosa M. PintóComments to Author 
Author affiliations: Author affiliations: University of Barcelona, Barcelona, Spain (U. Pérez-Sautu, M.I. Costafreda, A. Bosch, R.M. Pintó); Public Health Agency of Barcelona, Barcelona (J. Caylà, C. Tortajada); CatLab, Viladecavalls, Spain (J. Lite)

Main Article

Table 2

Neutralization assays of K34C8 MAb-escape variants that showed replacements at the same or very close positions as the mutated positions in the naturally-selected field variants isolated during 2005–2009*†

Mutant (position replaced) log Nt/N0 vaccine serum (HAVRIX) log Nt/N0 vaccine serum (Avaxim) log Nt/N0 convalescent-phase serum (HCS2) log Nt/N0 MAb K34C8
C6 (1170) –0.08 ± 0.14 –0.08 ± 0.14 –0.02 ± 0.04 –0.08 ± 0.14
P29 (1187) –0.70 ± 0.09 –0.30 ± 0.19 –0.70 ± 0.07 –0.37 ± 0.19
D23 (1217) –0.88 ± 0.02 –0.54 ± 0.01 –0.61 ± 0.07 –0.58 ± 0.12
HM175/43c –0.69 ± 0.09 –0.60 ± 0.05 –0.65 ± 0.05 –0.61 ± 0.10

*Assays were performed by using vaccine and convalescent-phase serum samples as well as K34C8 MAb. MAb, monoclonal antibody; HAVRIX, HAVRIX vaccine (GlaxoSmithKline, Rixenart, Belgium); Avaxim, Avaxim vaccine (Sanofi-Pasteur, Paris, France).
†Following the model of the hepatitis A virus protomer of Ming Luo (Figure 1). Three neutralization assays were performed with each antivaccine serum sample, the convalescent-phase serum sample, and the MAb K34C8. As controls, neutralization of the D23 H7C27 MAb escape variant (9) as well as that of the HM175/43c wild-type strain, was also measured. The highest dilution showing a log Nt/N0 = –0.60 (75% neutralization) of the wild-type strain was used to test the variants; Nt, the viral titer after neutralization; N0, the initial titer. Neutralization limits were the following: log Nt/N0>–0.26 (<45%) for resistant variants, –0.26>log Nt/N0>–0.60 (45%–75%) for partially resistant variants, and log Nt/N0<–0.60 (>75%) for sensitive variants (9).

Main Article

References
  1. Pintó  RM, Costafreda  MI, Bosch  A. Risk assessment in shellfish-borne outbreaks of hepatitis A. Appl Environ Microbiol. 2009;75:73505. DOIPubMed
  2. Wheeler  C, Vogt  TM, Armstrong  GL, Vaughan  G, Weltman  A, Nainan  OV, An outbreak of hepatitis A associated with green onions. N Engl J Med. 2005;353:8907. DOIPubMed
  3. Faber  MS, Stark  K, Behnke  SC, Schreier  E, Frank  C. Epidemiology of hepatitis A virus infections, Germany, 2007–2008. Emerg Infect Dis. 2009;15:17608.PubMed
  4. Stene-Johansen  K, Tjon  G, Schreier  E, Bremer  V, Bruisten  S, Ngui  SL, Molecular epidemiological studies show that hepatitis A virus is endemic among active homosexual men in Europe. J Med Virol. 2007;79:35665. DOIPubMed
  5. Costa-Mattioli  M, Napoli  AD, Ferre  V, Billaudel  S, Perez-Bercoff  R, Cristina  J. Genetic variability of hepatitis A virus. J Gen Virol. 2003;84:3191201. DOIPubMed
  6. Robertson  BH, Jansen  RW, Khanna  B, Totsuka  A, Nainan  OV, Siegl  G, Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. J Gen Virol. 1992;73:136577. DOIPubMed
  7. Sánchez  G, Bosch  A, Pintó  RM. Genome variability and capsid structural constraints of hepatitis A virus. J Virol. 2003;77:4529. DOIPubMed
  8. Sánchez  G, Bosch  A, Gomez-Mariano  G, Domingo  E, Pintó  RM. Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology. 2003;315:3442. DOIPubMed
  9. Aragonès  L, Bosch  A, Pintó  RM, Hepatitis  A. Virus mutant spectra under the selective pressure of monoclonal antibodies: codon usage constraints limit capsid variability. J Virol. 2008;82:1688700. DOIPubMed
  10. Aragonès  L, Guix  S, Ribes  E, Bosch  A, Pintó  RM. Fine-tuning translation kinetics selection as the driving force of codon usage bias in the hepatitis A virus capsid. PLoS Pathog. 2010;6:e1000797. DOIPubMed
  11. Luo  M, Rossmann  MG, Palmenberg  AC. Prediction of three-dimensional models for foot-and-mouth disease virus and hepatitis a virus. Virology. 1988;166:50314. DOIPubMed
  12. Ping  LH, Lemon  SM. Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J Virol. 1992;66:220816.PubMed
  13. Sánchez  G, Aragonès  L, Costafreda  MI, Ribes  E, Bosch  A, Pintó  RM. Capsid region involved in hepatitis a virus binding to glycophorin A of the erythrocyte membrane. J Virol. 2004;78:980713. DOIPubMed
  14. Weissman  S, Feucht  C, Moore  BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat. 2006;13:816. DOIPubMed
  15. Neilsen  GA, Bodsworth  NJ, Watts  N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis. 1997;176:10647. DOIPubMed

Main Article

1These authors contributed equally to this article.

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external